Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 17/20 | 0.85 |
| ▸ | AURKB | Q96GD4 | 13/20 | 0.85 |
| ▸ | EGFR | P00533 | 4/20 | 0.85 |
| ▸ | KDR | P35968 | 4/20 | 0.85 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.85 |
| ▸ | LCK | P06239 | 2/20 | 0.85 |
| ▸ | LYN | P07948 | 2/20 | 0.85 |
| ▸ | RET | P07949 | 2/20 | 0.85 |
| ▸ | HCK | P08631 | 2/20 | 0.85 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.85 |
| ▸ | KIT | P10721 | 2/20 | 0.85 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.85 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.85 |
| ▸ | FLT3 | P36888 | 2/20 | 0.85 |
| ▸ | MST1R | Q04912 | 2/20 | 0.85 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.85 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.85 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.85 |
| ▸ | FYN | P06241 | 1/20 | 0.85 |
| ▸ | RAB6A | P20340 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491964 | 0.98 | AURKA (0.82) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL3490369 | 0.96 | AURKA (0.79) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL3489643 | 0.95 | AURKA (0.77) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL613581 | 0.95 | AURKA (0.91) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL1345032 | 0.95 | AURKA (0.86) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL12132714 | 0.92 | AURKA (0.90) | AURKAAURKBEGFRKDRRIPK2 | |
| Barasertib SCHEMBL613582 | 0.92 | AURKA (1.00) | AURKAAURKBEGFRKDRRIPK2 | |
| Barasertib SCHEMBL29368256 | 0.92 | AURKA (1.00) | AURKAAURKBEGFRKDRRIPK2 | |
| Barasertib SCHEMBL29720420 | 0.92 | AURKA (1.00) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL3860607 | 0.92 | AURKA (0.86) | AURKAAURKBEGFRKDRRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567358-B2 | Methods of treatment using N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide | ASTRAZENECA AB (SE) | 2017-02-14 | — | — | US | disclosed |
| US-20150307534-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-29 | — | — | US | disclosed |
| US-9018191-B2 | Phosphonoxy quinazoline derivatives and their pharmaceutical use | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2014-06-12 | — | — | US | disclosed |
| US-8268841-B2 | Phosphonoxy quinazoline derivatives and their pharmaceutical use | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| EP-2019832-B1 | PROCESS FOR THE PREPARATION OF PYRAZOLYLAMINOQUINAZOLINE DERIVATIVES COMPRISING A PHOSPHATE GROUP | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8063210-B2 | Process and intermediate | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| US-8063210-B2 | Process and intermediate | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| US-20100069412-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | disclosed |
| US-7625910-B2 | Co-crystal | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| EP-2027114-A1 | MALEATE CO-CRYSTAL OF AZD1152 | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| EP-2026808-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| US-20080045481-A1 | NOVEL CO-CRYSTAL | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| WO-2007132227-A1 | MALEATE CO-CRYSTAL OF AZD1152 | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132215-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270384-A1 | PROCESS AND INTERMEDIATE | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270384-A1 | PROCESS AND INTERMEDIATE | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| EP-1847539-A1 | Quinazoline derivatives | AstraZeneca AB (SE) | 2007-10-24 | — | — | EP | disclosed |
| EP-1578755-B1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2007-08-22 | — | — | EP | disclosed |
| US-20060116357-A1 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270384-A1 | PROCESS AND INTERMEDIATE | PIK3CG, PIK3CA, PIK3CB | AURKA 52/4885AURKB 134/4885EGFR 737/4885 |
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | PLK2, ABL1, CYP3A5 | AURKA 220/4885AURKB 575/4885EGFR 2101/4885 |
| US-20080045481-A1 | NOVEL CO-CRYSTAL | AURKA, AURKC, BUB1 | AURKA 1/4885AURKB 6/4885EGFR 524/4885 |
| US-20150307534-A1 | CHEMICAL COMPOUNDS | ABL1, NQO1, NQO2 | AURKA 492/4885AURKB 634/4885EGFR 1121/4885 |
| US-20100069412-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | PLK2, ABL1, CYP3A5 | AURKA 220/4885AURKB 575/4885EGFR 2101/4885 |
| US-20060116357-A1 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885EGFR 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.